The largest database of trusted experimental protocols

111 protocols using cpg odn 1826

1

Formulations of LRV1c Vaccine Candidate

Check if the same lab product or an alternative is used in the 5 most similar protocols
LRV1c + SFI: 168 μL of 1.2 mg/mL LRV1c protein solution in PBS (Sigma) (202 μg of protein) were added to 832 μL of SFI (0.2% DMSO (Applichem) in sterile 0.9% NaCl (SFI, Braun).
LRV1c + SWE: 168 μL of 1.2 mg/mL LRV1c protein solution in PBS were diluted into 232 μL of WFI. The solution was added to 500 μL of SWE. The mixture was vortexed 5s and left standing at least 30 minutes at room temperature before administration.
LRV1c + SM: 168 μL of 1.2 mg/mL LRV1c protein solution in PBS were diluted into 216 μL of WFI and 300 μL of the solution were added to 700 μL of SM. The mixture was vortexed 5s and left standing at least 30 minutes at room temperature before administration.
LRV1c + LQ: 168 μL of 1.2 mg/mL LRV1c protein solution in PBS were diluted into 432 μL of sterile PBS. 600 μL of the solution were added to 400 μL of LQ and left standing at least 30 minutes at room temperature before administration.
LRV1c + Montanide ISA 720: 700 μL of Montanide ISA-720 were added to 168 μL of 1.2 mg/mL of LRV1c protein solution in PBS by using two syringes connected by a female luer lock adapter until a homogenous emulsion was obtained (50 times).
LRV1c + CpG: 168 μL of 1.2 mg/mL LRV1c protein solution in PBS were diluted into 782 μL in PBS (Sigma) and added 50 μL (20mg/mL) of CpG ODN-1826 (InvivoGen), for a final amount of 10 μg of LRV1c and 50 μg of CpG ODN-1826 for each mouse.
+ Open protocol
+ Expand
2

Chlamydia abortus Antigen Preparation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Stock preparations of C. abortus strain P16 and strain B577 (Dr. Bernhard Kaltenboeck, Auburn University, Alabama) were generated by propagating elementary bodies (EBs) in BGMK cells as previously described [21 (link)] and stored at −70°C. C. abortus antigen was prepared by UV-inactivation of EBs for 3 h. Purified Fms-like tyrosine kinase 3 (Flt3) ligand (FL) was obtained from R&D Systems, Minneapolis, MN and CpG 1826 ODN was obtained from InvivoGen, San Diego, CA.
Female C57BL/6 mice (aged 6 to 8 weeks) were obtained from The Jackson Laboratory (Bar Harbor, ME). Animals were housed in the animal facility of Morehouse School of Medicine and studies were performed in compliance with institutional IACUC and Federal guidelines.
+ Open protocol
+ Expand
3

Chlamydia abortus Propagation and Antigen Preparation

Check if the same lab product or an alternative is used in the 5 most similar protocols
C. abortus strains CP16 (Chinese Institute of Veterinary Drug Control, Beijing, China) and B577 (ATCC® VR-656™ (obtained from Dr. Bernhard Kaltenboeck, Auburn University, Alabama) were propagated and purified in Buffalo Green Monkey Kidney (BGMK) cells (ATCC cat# PTA-4594) as previously described (Li et al., 2005 (link)). Organisms were purified as elementary bodies (EBs) and stored in aliquots at −80°C until use. C. abortus antigen was prepared by UV-inactivation of EBs for 3 h followed by sonication using a Sonic Dismembrator Model 505 (Thermo Fisher Scientific, Rockford, IL). VCG were generated by genetic inactivation following protein E-mediated lysis as described previously (Eko et al., 2000 (link)). VCG preparations were stored at room temperature until use. Purified mouse Fms-like tyrosine kinase 3 (Flt3) ligand (FL) was obtained from R&D Systems (Minneapolis, MN), CpG 1826 ODN was obtained from InvivoGen (San Diego, CA) and lipopolysaccharide (LPS) was purchased from Sigma (St. Louis, MO).
+ Open protocol
+ Expand
4

Intranasal and Intramuscular Influenza Infection

Check if the same lab product or an alternative is used in the 5 most similar protocols
Intranasal infections were performed with influenza A/HKx31 (H3N2) at 30,000 50% egg infectious doses (EID50); intramuscular infections were performed with influenza A/HK×31 (H3N2) at 1×106 EID5026 (link). Influenza A/PR8 (H1N1) at 6,000 EID50 was used for heterologous challenge of vaccinated and infected mice. Peptides used for lung antigen dosing were InfluenzaNP311-325 (QVYSLIRPNENPAHK) and InfluenzaNP366-374 (ASNENMETM) at 5μg, as indicated. TLR agonist ODN 1826 (CpG) (InVivoGen) was administered at 5μg to induce inflammation. Peptides and/or TLR agonist were administered in 30μl of PBS intranasally. For influenza A/PR8 (H1N1) challenge, animals reaching defined endpoints of less than 75% original weight were humanely euthanized by 2,2,2-Tribromoethanol (Avertin) overdose (600mg/kg) followed by brachial exsanguination. No other analgesics or anesthetics were administered during the time course.
+ Open protocol
+ Expand
5

Microneedle Patch for Immunomodulatory Delivery

Check if the same lab product or an alternative is used in the 5 most similar protocols
All reagents and solvents were purchased from Sigma Aldrich unless otherwise stated. Sodium hyaluronate (60 kDa) was obtained from LifeCore Medical with a purity of at least 95%. NHS-terminated 8-arm PEG was purchased from Creative PEG Works. Microneedle PDMS custom-made molds (11 X 11 needles with a height 600 µm, base width of 300 µm, and tip to tip spacing of 600 µm) were obtained from Blueacre Technology. Arginine peptide (H-Cys-Arg-Arg-Arg-NH2) was obtained from CPC Scientific with a purity of at least 90%. ODN 1826 (CpG) and control ODN 1826 were purchased from InvivoGen.
+ Open protocol
+ Expand
6

Intranasal and Intramuscular Influenza Infection

Check if the same lab product or an alternative is used in the 5 most similar protocols
Intranasal infections were performed with influenza A/HKx31 (H3N2) at 30,000 50% egg infectious doses (EID50); intramuscular infections were performed with influenza A/HK×31 (H3N2) at 1×106 EID5026 (link). Influenza A/PR8 (H1N1) at 6,000 EID50 was used for heterologous challenge of vaccinated and infected mice. Peptides used for lung antigen dosing were InfluenzaNP311-325 (QVYSLIRPNENPAHK) and InfluenzaNP366-374 (ASNENMETM) at 5μg, as indicated. TLR agonist ODN 1826 (CpG) (InVivoGen) was administered at 5μg to induce inflammation. Peptides and/or TLR agonist were administered in 30μl of PBS intranasally. For influenza A/PR8 (H1N1) challenge, animals reaching defined endpoints of less than 75% original weight were humanely euthanized by 2,2,2-Tribromoethanol (Avertin) overdose (600mg/kg) followed by brachial exsanguination. No other analgesics or anesthetics were administered during the time course.
+ Open protocol
+ Expand
7

Murine models for antigen-specific immunity

Check if the same lab product or an alternative is used in the 5 most similar protocols
Vesicular stomatitis virus strain expressing OVA (VSV-OVA, Indiana)35 (link) and Listeria monocytogenes strain expressing OVA (LM-OVA)36 (link) have been previously described. Infections were performed i.v. with 105 pfu VSV-OVA or 103 cfu LM-OVA per mouse. Intranasal infections were performed with 1 × 103 pfu Influenza A virus (WSN-OVA)37 (link). Vaccinia-Ova (rVV-OVA) has been previously described38 (link) and was administered via skin scarification at 105 pfu. Some VSV infected mice were treated with 50 ug ODN 1826 CpG (InvivoGen, San Diego, CA) i.p. in PBS, 90 minutes after infection.
+ Open protocol
+ Expand
8

Subcutaneous OVA/CpG Vaccination Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Vaccination with OVA/CpG was performed by subcutaneous injection of 200 µg endotoxin-free OVA (Invivogen; vac-pOVA-100) + 10 µg endotoxin-free ODN1826 CpG (Invivogen; tlrl-1826-1) in 200 µl PBS subcutaneously into the right flank.
+ Open protocol
+ Expand
9

Immunotherapy Efficacy in Murine Tumor Model

Check if the same lab product or an alternative is used in the 5 most similar protocols
E0771 tumor cells (50,000 cells) were implanted into immunocompentent C57/Bl6 mice in saline, MT, PEG-RGD, and PEG-RDG, and tumors measured every 48 h. Animals were randomized among cages and researchers were blinded to groups. Animals were randomly pre-assigned to a therapeutic group. Once tumors reached ~100 mm3 in ellipsoidal volume (treatment day 0 [d0]), animals received first treatment of CpG, ICB, or isotype mAb based on pre-assigned therapeutic group. Animals assigned to receive CpG therapy received 3 μg ODN 1826 (CpG, InvivoGen, Inc., San Diego, CA) in 30 μL sterile saline intratumorally on d0 and d7. Animals assigned to receive ICB therapy were given 100 μg each of αPD1 (BioXCell) and αCTLA-4 (clone 9H10, BioXCell) in 100 μL sterile saline intraperitoneally on day 0, 3, and 6. Animals assigned to isotype mAb group were given 100 μg each of rat IgG2a anti-trinitrophenol (BioXCell) and polyclonal Armenian hamster IgG (BioXCell) intraperitoneally on day 0, 3, and 6. Tumor volume and animal weight was monitored every 48 h until animals reached the predetermined endpoint (tumor size of 15 mm in any dimension or if the animal displayed signs of illness or distress).
+ Open protocol
+ Expand
10

Comprehensive Immunology Research Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
All fluorescently tagged antibodies, αCD28/CD3 antibodies, ELISA kits, RBC lysis buffer, Foxp3/Transcription Factor Staining Buffer Set, EDTA, and Cell Proliferation Dye eFluor 670 were purchased from Invitrogen. All inhibitors (modulators) were purchased from MedChemExpress. Bovine serum albumin (BSA) was purchased from VWR Life Science. HBSS, DPBS, PBS, DMEM, RPMI 1640, AIM-V medium, FBS, HI-FBS, HEPES, and non-essential amino acid solutions were purchased from Gibco. RAW-Dual cells, RAW Blue cells, QB buffer and reagent, EndoFit Ovalbumin (OVA), ODN 1826 (CpG), and all other TLR agonists were purchased from InvivoGen. Spleen Dissociation Medium and EasySep Mouse T-Cell Isolation Kit were purchased from STEMCELL Technologies. β-Mercaptoethanol was purchased from MP Biomedicals. Cell Activation Cocktail (without Brefeldin A), Recombinant Mouse GM-CSF (carrier-free) (20 ng/mL), and LEGENDplex MU Th1/Th2 Panel (8-plex) Kit were purchased from BioLegend. ProT2 MHC Class II tetramers and Pro5 MHC Class I pentamers were purchased from ProImmune. All plates, unless noted otherwise, were purchased from Thermo Fisher Scientific.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!